Acorda Therapeutics, Inc. a biopharmaceutical company, develops and markets therapies for neurological disorders in the United States. The company markets Ampyra, an oral drug to improve gait in patients with multiple sclerosis; Inbrija for the treatment of OFF periods in Parkinson's disease.
Its latest quarterly report represents an earnings surprise of 3.15%. The drugmaker was expected to post a loss of $1.48 per share. Over the past four quarters, the company has beaten consensus EPS estimates three times.
$ACOR generated $152M in 2020, EBITDA growth of 44% and was able to increase its gross margin to 63.3%.
Its latest quarterly report represents an earnings surprise of 3.15%. The drugmaker was expected to post a loss of $1.48 per share. Over the past four quarters, the company has beaten consensus EPS estimates three times.
$ACOR generated $152M in 2020, EBITDA growth of 44% and was able to increase its gross margin to 63.3%.
Trade closed manually:
$4.40 June 17